StratDeck

Two stocks in Drug Manufacturers - General

Amgen vs Johnson & Johnson: profit, growth, debt and price compared

Amgen is stronger on 5 of 7 figures: profit margin, sales growth, price for its expected profit, dividend and price trend. Johnson & Johnson is stronger on 2: debt and analysts' view.

Figures as of 18 November 2026SEC EDGARYahoo Finance
Explore Amgen's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Amgen and Johnson & Johnson side by side
AmgenAMGNJohnson & JohnsonJNJ
Net marginStronger: 24.1%16.2%
Revenue growth, past yearStronger: +8.45%+5.86%
Debt to equity376.3%Stronger: 54.8%
Forward P/EStronger: 17.7×23.5×
Dividend yieldStronger: 2.27%1.94%
AnalystsHold · 29Stronger: Buy · 22
From its 200-day averageStronger: +14.8%+10.2%

Share price over the past year

  • Amgen+29.0%
  • Johnson & Johnson+36.3%

18 Nov 202518 Nov 2026

Amgen or Johnson & Johnson: which is stronger?

  • AMGN

    Which is more profitable?

    Amgen keeps more of each sale as profit: 24.1% against 16.2%.

  • AMGN

    Which is growing its sales faster?

    Amgen is growing its sales faster: +8.45% over the past year, against +5.86%.

  • JNJ

    Which has borrowed less?

    Johnson & Johnson has borrowed less: its debt is 54.8% of what its shareholders own, against 376.3% for Amgen.

  • AMGN

    Which costs less for the profit it is expected to make?

    Amgen costs less for the profit it is expected to make: 17.7× its forward earnings, against 23.5×.

  • AMGN

    Which pays more in dividends?

    Amgen pays more back in dividends for what a share costs: 2.27% a year, against 1.94%.

  • JNJ

    Which do analysts rate higher?

    Analysts are warmer on Johnson & Johnson: Buy, against Hold for Amgen.

  • AMGN

    Which is in the stronger price trend?

    Amgen's price is in the stronger trend: 14.8% above its 200-day average, against 10.2% above.

What each company does

AMGNAmgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Reports results on 2 February 2027

JNJJohnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

Reports results on 26 January 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.